NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Also, I wonder why he didn’t clarify the reason assessing PFS was so difficult? He could have easily written that it was due to pseudoprogression.

During the conduct of the trial, the limitations and difficulties of assessing progression-free survival became apparent, and, after completion of enrollment, the initial design was modified to restrict analyses to the overall survival outcomes of the 232 patients initially randomized to DCVax, which were to be compared with pooled historical control data inferred from published data.